233 related articles for article (PubMed ID: 30070748)
1. Role of fibroblast growth factor receptor 4 in cancer.
Tang S; Hao Y; Yuan Y; Liu R; Chen Q
Cancer Sci; 2018 Oct; 109(10):3024-3031. PubMed ID: 30070748
[TBL] [Abstract][Full Text] [Related]
2. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
3. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
4. Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?
Heinzle C; Erdem Z; Paur J; Grasl-Kraupp B; Holzmann K; Grusch M; Berger W; Marian B
Curr Pharm Des; 2014; 20(17):2881-98. PubMed ID: 23944363
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
Lang L; Teng Y
Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
[TBL] [Abstract][Full Text] [Related]
6. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
8. Making way for suppressing the FGF19/FGFR4 axis in cancer.
Prieto-Dominguez N; Shull AY; Teng Y
Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
[TBL] [Abstract][Full Text] [Related]
9. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
11. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
André F; Cortés J
Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
13. Advances and challenges in targeting FGFR signalling in cancer.
Babina IS; Turner NC
Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
16. FGF19 and cancer.
Lin BC; Desnoyers LR
Adv Exp Med Biol; 2012; 728():183-94. PubMed ID: 22396170
[TBL] [Abstract][Full Text] [Related]
17. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.
Saichaemchan S; Ariyawutyakorn W; Varella-Garcia M
Curr Mol Med; 2016; 16(1):40-62. PubMed ID: 26695695
[TBL] [Abstract][Full Text] [Related]
19. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
20. Targeting fibroblast growth factor pathways in endometrial cancer.
Winterhoff B; Konecny GE
Curr Probl Cancer; 2017; 41(1):37-47. PubMed ID: 28041631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
